Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
50 Results for "
DYRKA
" in MedChemExpress (MCE) Product Catalog:
Products (50)
50 Results for "DYRKA" in MCE Product Catalog:
3
3 Cited Publications
Target:
Forschungsgebiete:
DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor. DYRK1-IN-1 inhibits DYRK1A phosphorylation activity with an IC50 value of 220 nM. DYRK1-IN-1 can be used for the research of central nervous system penetrant DYRK1A chemical probe .
2
2 Cited Publications
Target:
Forschungsgebiete:
AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC50 of 7 nM .
1
1 Cited Publications
Target:
Forschungsgebiete:
Dyrk1A-IN-5 (Compound 5j) is a potent and selective DYRK1A inhibitor, with an IC50 of 6 nM. yrk1A-IN-5 exhibits significant selectivity for DYRK1B (IC50 = 600 nM) and CLK1 (IC50 = 500 nM), but shows almost no inhibition of DYRK2 (IC50 > 10 μM). Dyrk1A-IN-5 can be used for Down syndrome research .
Dyrk1A-IN-4 is a potent and orally active Dyrk1A inhibitor. Dyrk1A-IN-4 exhibits IC50s against DYRK1A and DYRK2 of 2 nM and 6 nM. Dyrk1A-IN-4 exhibits the inhibition of the DYRK1A pSer520 autophosphorylation in U2OS cells with an IC50 of 28 nM. Dyrk1A-IN-4 can be used for the studies of ovarian adenocarcinoma, neuroblastoma and cervical squamous cell carcinoma .
DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity .
Target:
Forschungsgebiete:
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC50=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .
Art. -Nr.: HY-161597
CAS. Nr.: 3061366-76-2
PROTAC DYRK2 degrader 1 is a DYRK2 PROTAC degrader with DC50 values of 1.607 μM (MDA-MB-231 cells) and 3.265 μM (HeLa cells), respectively. PROTAC DYRK2 degrader 1 induces DYRK2 degradation via the ubiquitin-proteasome system. It is applicable to the research of triple-negative breast cancer and cervical cancer .
Art. -Nr.: HY-176402
Target:
Forschungsgebiete:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Dyrk1A-IN-13 (Compound 1) is a DYRK1A inhibitor (IC50: 41 nM). Dyrk1A-IN-13 reduces LPS-induced NO production and has antioxidant and anti-inflammatory activities. Dyrk1A-IN-13 can be used in the research of Alzheimer's disease, cancer and diabetes .
Art. -Nr.: HY-139830
CAS. Nr.: 2858696-72-5
Target:
Forschungsgebiete:
Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
Art. -Nr.: HY-128758
CAS. Nr.: 1387090-01-8
DYRKs-IN-1 is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity .
Art. -Nr.: HY-128759
CAS. Nr.: 1386980-04-6
DYRKs-IN-2 (Example 132) is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity .
Art. -Nr.: HY-168265
CAS. Nr.: 3058626-26-6
Target:
Forschungsgebiete:
Dyrk1A-IN-11 (compound 166) is a potent dual-specificity tyrosine phosphorylation- regulated 1A (DYRK1A) inhibitor with an EC50 value of 0.0021 µM. Dyrk1A-IN-11 inhibits the Phospho-Tau (Thr212) with an EC50 value of 0.0361 µM .
Art. -Nr.: HY-161598
Forschungsgebiete:
DYRK2 ligand 1 is a target protein ligand of PROTAC DYRK2 degrader 1 (HY-161597). DYRK2 ligand 1 can be used to study cancer .
Art. -Nr.: HY-RS04098
Target:
Forschungsgebiete:
DYRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS04099
Target:
Forschungsgebiete:
Dyrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS04100
Target:
Forschungsgebiete:
Dyrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS04101
Target:
Forschungsgebiete:
DYRK3 Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS04102
Target:
Forschungsgebiete:
Dyrk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS04103
Target:
Forschungsgebiete:
Dyrk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS04104
Target:
Forschungsgebiete:
DYRK4 Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
